Why our work matters
RareSight's AI-supported rare-disease diagnostic acceleration platform is capable of reducing Germany’s average time-to-diagnosis of rare diseases by 1–2 years and could generate €2.7B–€8B annual fiscal and economic benefit, strengthening workforce participation, reducing disability-system burden, and improving national health-system efficiency at scale.
References:
Time to diagnosis and determinants of diagnostic delays of people living with a rare disease: results of a Rare Barometer retrospective patient survey | European Journal of Human Genetics (directly supports the premise that there is a large reducible delay window)
The cost of the diagnostic odyssey of patients with suspected rare diseases - PMC (The study concludes that shortening the diagnostic journey has “high potential to decrease the financial burden related to rare diseases")
The economic burden of diagnostic uncertainty on rare disease patients | BMC Health Services Research | Springer Nature Link (supports workforce participation effects, productivity recovery, and fiscal benefits from earlier diagnosis)
Putting rare diseases at the heart of the EU Life Sciences Strategy - EURORDIS-Rare Diseases Europe (supports the macroeconomic framing of the economic impact)
EU rare disease action plan (Policymakers already frame rare-disease delay as an economic issue. European Parliament and EURORDIS materials explicitly describe rare diseases as generating: sustained healthcare utilisation, reduced labour-market participation, productivity losses, and major system-level economic impacts.)
